Alterations of INK4ap16-p14ARF/INK4bp15 expression and telomerase activation in meningioma progression

Journal of Neuro-Oncology

Volumn 55, Issue 3, 2001, Pages 149-158

  Simon, M ^a   Park, T W ^b   Koster G ^a   Mahlberg, R ^a   Hackenbroch Jan Bostrom M ^a   Bostrom J ^a   Loning T ^c   Schramm, J ^a  

^a Neurochirurgische Universitätsklinik   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Meningioma progression; p10; p14ARF; p15; p16; Telomerase

Indexed keywords

MESSENGER RNA; PROTEIN P14; PROTEIN P15; PROTEIN P16; TELOMERASE; TRANSCRIPTION FACTOR;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; BENIGN TUMOR; CANCER CELL; CANCER GROWTH; CATALYSIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL IMMORTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENETIC DAMAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT MENINGIOMA; MALIGNANT TRANSFORMATION; MENINGIOMA; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; REGULATOR GENE; SENESCENCE; TRANS SPLICING; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CELL AGING; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENES, P16; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0035709111     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013863630293     Document Type: Article

References (44)

1. Atypical and anaplastic meningiomas: Radiology, surgery, radiotherapy, and outcome
2. Meningioma grading: An analysis of histologic parameters
3. Long-term prognosis for atypical and malignant meningiomas: A study of 71 surgical cases
4. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: A genetic model of meningioma progression
5. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression
6. Cancer cell cycles
7. Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas
8. Alternative reading frames of the INK4A tumour suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
9. Splicing into senescence: The curious case of p16 and p19ARF
10. Tumour suppression at the mouse INK4A locus mediated by the alternative reading frame product p19ARF
11. The INK4A tumour suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53
12. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4A locus deletion impairs both the Rb and p53 tumour suppression pathways
13. Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor
14. Replicative senescence: Implications for in vivo aging and tumour suppression
15. Can ends justify the means?: Telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells
16. Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence
17. p16(INK4a) and the control of cellular proliferative life span
18. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
19. Exogenous expression of p16INK4a is associated with decrease in telomerase activity
20. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A
21. The telomerase reverse transcriptase: Components and regulation
22. Refining the telomere-telomerase hypothesis of aging and cancer
23. A survey of telomerase activity in human cancer
24. Telomerase activation: One step on the road to cancer?
25. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells
26. Telomerase activity and expression of the telomerase catalytic subunit hTERT in meningioma progression
27. Meningiomas
28. Establishment and characterization of a human leptomeningeal cell line
29. ARF)/CDKN2B (p15) gene inactivation in malignant gliomas
30. Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme
31. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors
32. A cell cycle regulator potentially involved in genesis of many tumour types
33. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
34. Deletion of p16 and p15 genes in brain tumours
35. Analysis of cell cycle regulators p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas
36. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas
37. Detection of TP53 gene mutation in human meningiomas: A study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples
38. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer
39. Germ-line deletion involving the INK4-locus in familial proneness to melanoma and nervous system tumours
40. Absence of p16 mutations in malignant meningioma progression
41. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumours
42. 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
43. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia